Cellmid

Cellmid’s lead antibody, CAB102, effective in the rare kidney Disease: Cellmid Limited’s (ASX: CDY) stock has fallen 15.79% in three months as on September 12, 2018; meanwhile, four of its board members have increased their holdings. They are managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck. Dennis Eck has acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000. Meanwhile CDY has received positive outcome from its lead anti-midkine antibody, CAB102, in the rare kidney disease, FSGS. With the use of CAB102, the kidney injury and preserved renal function has reduced in an experimental model of Focal Segmental Glomerulosclerosis (FSGS). The Preclinical desired result in the rare kidney disorder FSGS will allow  the company to apply for Orphan Drug application with FDA and EMA to commence. Based on the foregoing, we believe that this is a stock to watch for, while it trades at the current price of $ 0.395.
 

Imugene

Completes Phase 1b Cancer Vaccine Trial Recruitment: Imugene Limited (ASX: IMU), an immuno-oncology focused biopharmaceutical company, is engaged in the development of PD-1, HER-1, HER-2, HER-3, VEGF, IGF-1R cancer immunotherapies. The company’s lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptor, such as gastric, breast, ovarian, lung, and pancreatic cancers. IMU stock rose after the company completed the recruitment for its Phase 1b clinical trial of the HER-Vaxx cancer vaccine in HER-2 gastric cancer patients. This ongoing Phase 1b trial is testing three different doses of HER-Vaxx (IMU-131), which is in combination with current standard of care chemotherapy Cisplatin and either Fluorouracil or Capecitabine. The company considers the completion of recruitment to be an important milestone for the study and the many medical professionals who is looking for treatments for patients with advanced gastric cancer and who often have very few medical options. The company expects to complete the analysis in the coming months before establishing the optimal dose for a larger Phase 2 study. IMU has commenced the activities for Phase 2 preparation. Meanwhile, IMU stock has fallen 17.86% in three months as on September 12, 2018. Based on the foregoing, the stock needs to be watched out for any potential development that can boost the price. At the moment, the stock is trading at the current price of $ 0.022 (down 4.38% on September 13, 2018).
 

FY 18 Financial Performance (Source: Company Reports)
 

Medlab Clinical 

Granted a Licence to Export Cannabis: Medlab Clinical Ltd (ASX: MDC), is engaged in the sale of nutraceutical products and pharmaceutical research. The company provides research and product development in the field of chronic kidney disease, obesity, depression, pain management, and muscular-skeletal health. MDC stock rose after the company received a licence to export cannabis from the Office of Drug Control in Canberra. The export licence is related to its two cannabis-based medicines, NanaBis and NanaBidial. After receiving the export licence, MDC can undertake more formal overseas trade negotiations to supply their products legally overseas. It is worth noting that NanaBis and NanaBidial are based on group’s patented NanoCelle delivery platform that enables delivery of nano particles of the active pharmaceutical ingredients to the targeted site. Further, the patented technology has been validated by an independent research. In terms of financial performance, group’s FY18 revenue grew by 25% but loss also widened by 25% at the back of higher research costs. Meanwhile, MDC stock has risen 6.6% in past one month as on September 12, 2018 and is still just a bit over its 52-week lower level. Based on the foregoing, we give a “Hold” recommendation on the stock at the current price of $ 0.490.
 

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.